Zopiclone
imovane, zimovane
Depressant, Habit-forming, Common
A nonbenzodiazepine sedative sleep aid (Z-drug) which can have hallucinogenic effects if taken while awake. The drug is reported to cause users to have a metallic taste in the mouth for ~12h. The drug has been reported in cases to influence certain users to black out, redose excessively, and undertake dangerous activities such as driving.
IUPAC: (RS)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate | Formula: C17H17ClN6O3 | Molecular Mass: 388.808 g/mol
Liver disease, myasthenia gravis, severe chronic bronchitis, emphysema, sleep apnea, thyroid gland abnormalities, trimipramine, caffeine, alcohol, erythromycin, itraconazole, rifampicin, phenytoin, carbamazepine, ketoconazole, sulfaphenazole, and nefazodone
Australia: Prescription Only (S4) | United Kingdom: Controlled Drug (POM) | United States: Schedule IV
Protein Binding: 45 - 80% | Metabolism: various cytochrome P450 liver enzymes | Excretion: respiration (~50%) and urine (7 - 10 %)
GABA-A receptor positive allosteric modulator; Benzodiazepine receptor agonist
Chart shows bounded mass ranges in mg. See the table for all doses.
Threshold
Light
Common
Strong
Heavy
Oral
3.5mg
3.5-5mg
5-7.5mg
7.5-15mg
15-22.5mg
Onset
Duration
After Effects
Oral
0 to 15m
3h 30m to 9
1 to 12
Lethargy, tiredness, a dreamlike state while awake, can induce heavy sleep
Dependence potential of zopiclone studied in monkeys - http://www.ncbi.nlm.nih.gov/pubmed/6892368